A recombinant neuraminidase protein from human influenza viruses with the amino acid sequences replaced at specific positions at 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses to incur cross-protective immunity and be used for universal influenza vaccine development.

A recombinant neuraminidase protein from human influenza viruses with the amino acid sequences replaced at specific positions at 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses to incur cross-protective immunity and be used for universal influenza vaccine development.

The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the major markets, not including the potential of pandemic vaccines. The annual rate of influenza vaccine is approximately 12.6%. Our invention provides novel NA antigen design, which can be further used for developing “universal influenza vaccines”. Our invention has also been granted for patents in US and Taiwan.